The prognostic significance of del6q23 in chronic lymphocytic leukemia

Hadiyah Y. Audil; Paul J. Hampel; Daniel L. Van Dyke; Sara J. Achenbach; Kari G. Rabe; Stephanie A. Smoley; Timothy G. Call; Wei Ding; Min Shi; Curtis A. Hanson; Yucai Wang; Eli Muchtar; Amber B. Koehler; Susan M. Schwager; Jose F. Leis; Esteban Braggio; Susan L. Slager; Neil E. Kay; Saad S. Kenderian; Sameer A. Parikh

doi:10.1002/ajh.26168

The prognostic significance of del6q23 in chronic lymphocytic leukemia

Hadiyah Y. Audil, Paul J. Hampel, Daniel L. Van Dyke, Sara J. Achenbach, Kari G. Rabe, Stephanie A. Smoley, Timothy G. Call, Wei Ding, Min Shi, Curtis A. Hanson, Yucai Wang, Eli Muchtar, Amber B. Koehler, Susan M. Schwager, Jose F. Leis, Esteban Braggio, Susan L. Slager, Neil E. Kay, Saad S. Kenderian, Sameer A. Parikh

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	E203-E206
Journal	American journal of hematology
Volume	96
Issue number	6
DOIs	https://doi.org/10.1002/ajh.26168
State	Published - Jun 1 2021

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.26168

Cite this

Audil, H. Y., Hampel, P. J., Van Dyke, D. L., Achenbach, S. J., Rabe, K. G., Smoley, S. A., Call, T. G., Ding, W., Shi, M., Hanson, C. A., Wang, Y., Muchtar, E., Koehler, A. B., Schwager, S. M., Leis, J. F., Braggio, E., Slager, S. L., Kay, N. E., Kenderian, S. S., & Parikh, S. A. (2021). The prognostic significance of del6q23 in chronic lymphocytic leukemia. American journal of hematology, 96(6), E203-E206. https://doi.org/10.1002/ajh.26168

Audil, HY, Hampel, PJ, Van Dyke, DL, Achenbach, SJ, Rabe, KG, Smoley, SA, Call, TG, Ding, W, Shi, M, Hanson, CA, Wang, Y, Muchtar, E, Koehler, AB, Schwager, SM, Leis, JF, Braggio, E , Slager, SL , Kay, NE , Kenderian, SS & Parikh, SA 2021, 'The prognostic significance of del6q23 in chronic lymphocytic leukemia', American journal of hematology, vol. 96, no. 6, pp. E203-E206. https://doi.org/10.1002/ajh.26168

@article{dfe4d1b4e3c5489fb3cad4c9294ab04a,

title = "The prognostic significance of del6q23 in chronic lymphocytic leukemia",

author = "Audil, {Hadiyah Y.} and Hampel, {Paul J.} and {Van Dyke}, {Daniel L.} and Achenbach, {Sara J.} and Rabe, {Kari G.} and Smoley, {Stephanie A.} and Call, {Timothy G.} and Wei Ding and Min Shi and Hanson, {Curtis A.} and Yucai Wang and Eli Muchtar and Koehler, {Amber B.} and Schwager, {Susan M.} and Leis, {Jose F.} and Esteban Braggio and Slager, {Susan L.} and Kay, {Neil E.} and Kenderian, {Saad S.} and Parikh, {Sameer A.}",

note = "Funding Information: Results of this study were presented in part at the 25th European Hematology Association Congress held virtually in June 2020. The conduct of this research was supported in part by the Henry J. Predolin Foundation. Sameer A. Parikh and Saad S. Kenderian also acknowledge support from the Mayo Clinic K2R Career Development Program. Funding Information: S.A.P.: Research funding has been provided to the institution from Pharmacyclics, Janssen, AstraZeneca, TG Therapeutics, Merck, AbbVie, and Ascentage Pharma for clinical studies in which S.A.P. is a principal investigator. He has also participated in advisory board meetings of Pharmacyclics, AstraZeneca, Genentech, GlaxoSmithKline, Innate Pharma, and AbbVie (he was not personally compensated for his participation). N.E.K.: Research funding from: Acerta Pharm, Pharmacyclics, MEI Pharma, and Tolero. He is on a data safety monitoring committee for: Agios Pharm, Celgene, Sunesis, Cytomx Therapeutics, Morpho‐Sys, Rigel Pharm and Juno Therapeutics. He is on an advisory Board for Astra Zeneca, Cytomx Therapeutics, Pharmacyclics Dava Oncology, Acerta Pharma BV, and Juno Therapeutics. S.S.K.: S.S.K. is an inventor on patents in the field of CAR immunotherapy that are licensed to Novartis (through an agreement between Mayo Clinic, University of Pennsylvania, and Novartis), Humanigen (through Mayo Clinic), Morphosys (through Mayo Clinic), Tolero (through Mayo Clinic), and Mettaforge (through Mayo Clinic). S.S.K. receives research funding from Kite, Gilead, Juno, Celgene, Novartis, Humanigen, MorphoSys, Tolero, Sunesis, Leahlabs and Lentigen. S.S.K. has participated in consultancy with Torque, Leahlabs, and Kiniksa. S.S.K. has participated in scientific advisory board meetings of Juno, Kite, and Humanigen, and data safety monitoring board meetings of Humanigen. W.D.: Research funding from Merck and DTRM. Advisory board: Merck and Octapharma (no personal compensation). Y.W.: Research funding (to the institution) from Incyte, InnoCare, Norvatis, and Genentech. E.B.: E.B. is a consultant of DASA. All other authors declare no competing financial interests. ",

year = "2021",

month = jun,

day = "1",

doi = "10.1002/ajh.26168",

language = "English (US)",

volume = "96",

pages = "E203--E206",

journal = "American journal of hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "6",

}

TY - JOUR

T1 - The prognostic significance of del6q23 in chronic lymphocytic leukemia

AU - Audil, Hadiyah Y.

AU - Hampel, Paul J.

AU - Van Dyke, Daniel L.

AU - Achenbach, Sara J.

AU - Rabe, Kari G.

AU - Smoley, Stephanie A.

AU - Call, Timothy G.

AU - Ding, Wei

AU - Shi, Min

AU - Hanson, Curtis A.

AU - Wang, Yucai

AU - Muchtar, Eli

AU - Koehler, Amber B.

AU - Schwager, Susan M.

AU - Leis, Jose F.

AU - Braggio, Esteban

AU - Slager, Susan L.

AU - Kay, Neil E.

AU - Kenderian, Saad S.

AU - Parikh, Sameer A.

N1 - Funding Information: Results of this study were presented in part at the 25th European Hematology Association Congress held virtually in June 2020. The conduct of this research was supported in part by the Henry J. Predolin Foundation. Sameer A. Parikh and Saad S. Kenderian also acknowledge support from the Mayo Clinic K2R Career Development Program. Funding Information: S.A.P.: Research funding has been provided to the institution from Pharmacyclics, Janssen, AstraZeneca, TG Therapeutics, Merck, AbbVie, and Ascentage Pharma for clinical studies in which S.A.P. is a principal investigator. He has also participated in advisory board meetings of Pharmacyclics, AstraZeneca, Genentech, GlaxoSmithKline, Innate Pharma, and AbbVie (he was not personally compensated for his participation). N.E.K.: Research funding from: Acerta Pharm, Pharmacyclics, MEI Pharma, and Tolero. He is on a data safety monitoring committee for: Agios Pharm, Celgene, Sunesis, Cytomx Therapeutics, Morpho‐Sys, Rigel Pharm and Juno Therapeutics. He is on an advisory Board for Astra Zeneca, Cytomx Therapeutics, Pharmacyclics Dava Oncology, Acerta Pharma BV, and Juno Therapeutics. S.S.K.: S.S.K. is an inventor on patents in the field of CAR immunotherapy that are licensed to Novartis (through an agreement between Mayo Clinic, University of Pennsylvania, and Novartis), Humanigen (through Mayo Clinic), Morphosys (through Mayo Clinic), Tolero (through Mayo Clinic), and Mettaforge (through Mayo Clinic). S.S.K. receives research funding from Kite, Gilead, Juno, Celgene, Novartis, Humanigen, MorphoSys, Tolero, Sunesis, Leahlabs and Lentigen. S.S.K. has participated in consultancy with Torque, Leahlabs, and Kiniksa. S.S.K. has participated in scientific advisory board meetings of Juno, Kite, and Humanigen, and data safety monitoring board meetings of Humanigen. W.D.: Research funding from Merck and DTRM. Advisory board: Merck and Octapharma (no personal compensation). Y.W.: Research funding (to the institution) from Incyte, InnoCare, Norvatis, and Genentech. E.B.: E.B. is a consultant of DASA. All other authors declare no competing financial interests.

PY - 2021/6/1

Y1 - 2021/6/1

UR - http://www.scopus.com/inward/record.url?scp=85103681706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85103681706&partnerID=8YFLogxK

U2 - 10.1002/ajh.26168

DO - 10.1002/ajh.26168

M3 - Letter

C2 - 33749852

AN - SCOPUS:85103681706

SN - 0361-8609

VL - 96

SP - E203-E206

JO - American journal of hematology

JF - American journal of hematology

IS - 6

ER -

The prognostic significance of del6q23 in chronic lymphocytic leukemia

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this